Navigation Links
Novavax Opens Its First U.S. Vaccine Plant
Date:5/1/2008

otechnology company, creating novel vaccines to address a broad range of infectious diseases worldwide using advanced proprietary virus-like particle (VLP) technology. The Company produces these VLP based, highly potent, recombinant vaccines utilizing a new, efficient manufacturing solution.

Forward-Looking Statements

Statements herein relating to future financial or business performance, conditions or strategies and other financial and business matters, including expectations regarding future revenues, operating expenses, and clinical developments are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Novavax cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the failure by Novavax to secure and maintain relationships with collaborators; risks relating to the early stage of Novavax's product candidates under development; uncertainties relating to clinical trials; results of further animal and human testing may result in data inconsistent with previously announced data or with our expectations; risks relating to the commercialization, if any, of Novavax's proposed product candidates; dependence on the efforts of third parties; dependence on intellectual property; competition for clinical resources and patient enrollment from drug candidates in development by other companies with greater resources and visibility, and risks that we may lack the financial resources and access to capital to fund our operations. Further information on the factors and risks that could affect Novavax's business, financial conditions and results of operations, is contained in Novavax's filings with the U.S. Securities and Exchange Commission, which are available at http://www.sec.gov. These forward-looking statements sp
'/>"/>

SOURCE Novavax, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Novavax CEO to Present at the World Vaccine Congress 2008
2. Graceway Pharmaceuticals, LLC(TM) Announces Completed Acquisition of All Assets Related to Estrasorb(R) Product Line in North America From Allergan, Inc. (NYSE: AGN) and Novavax, Inc. (Nasdaq: NVAX)
3. Novavax Enters Into Estrasorb(R) Asset Sale and Supply Agreements with Graceway Pharmaceuticals, LLC
4. Novavax CEO to Present at BIO CEO & Investor Conference
5. Cytochroma opens U.S. headquarters in Illinois
6. Hologic, Inc. to Release Second Quarter Fiscal 2008 Operating Results Thursday, May 1st Before Market Opens
7. Alta Bates Summit Medical Center Opens Two Warm, Supportive Patient Centers: Carol Ann Read Breast Health Center and Family Resource Center
8. Transgenomic Opens Pharmacogenomics Laboratory in China
9. Finesse Solutions Opens New E-Store for Sensors
10. GRAS Status Opens Door to U.S. Food Industry
11. Antibody Engineering Company f-Star Opens Second Research Site in Cambridge, UK
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... (PRWEB) March 26, 2015 WriteResult, a ... with researchers from Yale University’s School of Public Health ... study participants during a 4 month-long project. The goal ... providing low income families with free access to fresh ... and diet-related health concerns like high blood pressure, diabetes ...
(Date:3/25/2015)... 25, 2015 The surging prevalence ... have fuelled social media growth, with over 50% ... in social networking. Insurance companies are making use ... clients and promote a diversity of their services ... increasingly exploiting social networking services as part of ...
(Date:3/25/2015)... An increase of awareness related to benefits of ... nutrients, regulatory changes and concerns related to consumer safety ... natural astaxanthin over the past few years. Producers of ... to satisfy the rising demand. , The global ... in nutraceuticals, aqua feed, food and beverages and cosmetics) ...
(Date:3/25/2015)... LOUIS and the HAGUE, Netherlands ... of two-year results of LES Stimulation therapy for chronic ... the journal Surgery [ Surgery . ... efficacy of its minimally-invasive therapy. The ... average duration of 11 years and taking prescribed daily ...
Breaking Biology Technology:Yale and New Haven Farms Improving Patient Health with WriteResult's myPROpad™ 2Yale and New Haven Farms Improving Patient Health with WriteResult's myPROpad™ 3Social Media Role in Global Insurance Industry Examined by Timetric in New Market Research Report Published at MarketPublishers.com 2Social Media Role in Global Insurance Industry Examined by Timetric in New Market Research Report Published at MarketPublishers.com 3Global Astaxanthin Market to Reach Value of USD 1.1 billion by 2020, Expects Industry Experts in New Report Available at MarketPublishers.com 2EndoStim LES Stimulation therapy demonstrates long term safety and efficacy results in treating reflux patients 2EndoStim LES Stimulation therapy demonstrates long term safety and efficacy results in treating reflux patients 3
... (OTC:,SPOM - News), a leading developer of biosensor and ... that it,has appointed Med Tech and Med Care Associates ... market. , Med Tech and ... healthcare industry and operate with manufacturers,of medical products and ...
... Md., Feb. 17 Human Genome Sciences, Inc. (Nasdaq: ... GSK ) has initiated a Phase 3 ... tolerability of Syncria (R) (albiglutide) in the long-term ... result, HGS will receive a $9 million milestone payment ...
... at the 19th Conference of the Asian Pacific ... Demonstrated Favorable Pharmacokinetics and Significant Reduction in Viral ... privately held biopharmaceutical company, today announced results from ... a controlled release version of nitazoxanide in the ...
Cached Biology Technology:SPO Medical Appoints New US Sales Rep Groups 2SPO Medical Appoints New US Sales Rep Groups 3Human Genome Sciences to Receive $9 Million Milestone Payment Related to GlaxoSmithKline Initiation of Phase 3 Clinical Trial of Syncria(R) in Type 2 Diabetes 2Human Genome Sciences to Receive $9 Million Milestone Payment Related to GlaxoSmithKline Initiation of Phase 3 Clinical Trial of Syncria(R) in Type 2 Diabetes 3Human Genome Sciences to Receive $9 Million Milestone Payment Related to GlaxoSmithKline Initiation of Phase 3 Clinical Trial of Syncria(R) in Type 2 Diabetes 4Romark Announces Presentation of New Data for Controlled Release Nitazoxanide in Chronic Hepatitis C 2Romark Announces Presentation of New Data for Controlled Release Nitazoxanide in Chronic Hepatitis C 3Romark Announces Presentation of New Data for Controlled Release Nitazoxanide in Chronic Hepatitis C 4
(Date:3/17/2015)... , March 17, 2015  MecklerMedia Corporation ... largest exhibition for service robots ever held in ... takes place on May 11-13, 2015 at the ... exhibitors for the event include: Acorn Product Development; ... EZ-Robot; Infranor; Kinova Robotics; Littler; NewBotic Corporation; Neya ...
(Date:3/12/2015)... MOUNTAIN VIEW, Calif. , March 12, 2015 ... EDTLOCATION:Online, with Complimentary Registration here: http://bit.ly/1G7Os0L . ... Program Manager Aravind SeshagiriPhoto - http://photos.prnewswire.com/prnh/20150311/181111 ... future in order to compete in several different ... the market is currently witnessing an uptrend. ...
(Date:3/10/2015)... , March 10, 2015   Tute Genomics , ... been selected by next-generation sequencing company PrimBio Research ... exome and targeted gene panel interpretation. PrimBio, ... adopted the most current technologies to support the work ... The company offers two types of exome sequencing services: ...
Breaking Biology News(10 mins):MecklerMedia's RoboUniverse New York Announces Sponsors and Exhibitors, May 11-13, 2015 2Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 2Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 3PrimBio Research Selects Tute as Whole Exome Analysis Provider, Creating Integrated, End-to-End Solution for Next-Generation Sequencing & Data Analysis 2PrimBio Research Selects Tute as Whole Exome Analysis Provider, Creating Integrated, End-to-End Solution for Next-Generation Sequencing & Data Analysis 3
... lacking a special protein found only in germ-line cells ... to a new study from researchers at the University ... of Human Reproduction in Penn's Center for Research in ... investigations point the way to a new type of ...
... In a recent study published in the Journal of ... to play a purely structural and inert role in ... Using antagonists for this molecule, the researchers were able ... drug treatment. , The research appears as the "Paper ...
... of neuroscientists have been indoctrinated into believing that ... by a communication network of brain cells, or ... message called a neurotransmitter. Either neurons release a ... an electrical discharge and enhancing brain activity, or ...
Cached Biology News:Of mice and men's (and women's) contraceptives 2New polysaccharide may help combat multidrug resistance in cancer 2Researchers make surprise discovery that some neurons can transmit three signals at once 2Researchers make surprise discovery that some neurons can transmit three signals at once 3
... designed to rapidly and reliably amplify unknown ... Technology. APAgene provides hassle-free, ready-to use components, ... ingredients are provided in each kit. The ... gap filling, localized cloning of genomic DNA, ...
Protein YIPF6 (YIP1 family member 6). [Source:Uniprot/SWISSPROT;Acc:Q96EC8] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Collected from animals of U.S. origin.Collected from animals of U.S. origin. *Can be used in cell growth studies and immunoassays. *Sterility tested, * Mycoplasma tested upon request, *Endoto...
...
Biology Products: